Solara Active Pharma Sciences Limited

BSE: 541540 NSE: SOLARA
Solara Active Pharma Sciences Limited - pharma in Thane, Maharashtra, India. FY 2026 financials and compliance.
CIN L24230MH2017PLC291636 Incorporated 23 February 2017 ROC Mumbai HQ Thane, Maharashtra, India
Active Listed - NSE: SOLARA · BSE: 541540 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹1,368.98 Cr
▲ 6.64% YoY
EBITDA · FY 2026
₹192.91 Cr
▼ 10.11% YoY
Net profit · FY 2026
-₹7.41 Cr
▼ 1472.22% YoY
Authorised capital
₹120 Cr
Registered with MCA
Paid-up capital
₹44.49 Cr
Issued & subscribed
Open charges
₹1,799.4 Cr
Satisfied ₹2,310.69 Cr
Company age
9 yrs
Est. 2017
Employees · EPFO
1,656
Latest available

About Solara Active Pharma Sciences Limited

Data last updated: 22 December 2025

Solara Active Pharma Sciences Limited is a public limited company based in Thane, Maharashtra, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 23 February 2017, the company has been in operation for over 9 years.

Registered with ROC Mumbai under CIN L24230MH2017PLC291636. Listed on BSE: 541540 and NSE: SOLARA.

Capital: an authorised share capital of ₹120 Cr and a paid-up capital of ₹44.49 Cr. Formerly known as Ssl Pharma Sciences Limited. It is led by directors including Poorvank Purohit and Rajiv Vijay Nabar.

Last AGM: 25 September 2025. Financial statements filed for year ended 31 March 2025. Office: Sector 30, Thane, Maharashtra.

As per the financials filed for FY 2025, the company reported a revenue of ₹1,292.08 Cr, a growth of 0% compared to the previous year.

The company has a workforce of approximately 1,656 employees as per the latest available data. Its group structure includes 2 subsidiaries.

The company is associated with 1 brand - Solara Active Pharma Sciences. As per MCA filings, the company has open charges of ₹1,799.4 Cr and satisfied charges of ₹2,310.69 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website solara.co.in.

Company Details of Solara Active Pharma Sciences Limited
CIN L24230MH2017PLC291636
Registration Number 291636
Incorporation Date 23 February 2017
ROC Mumbai
Listing Status Listed (BSE: 541540, NSE: SOLARA)
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Sandeep Shashikantha Rao Ceo Poorvank Purohit Managing Director Sarat Kumar Asuri Cfo
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    solara.co.in
  • Social Media
    **************
  • Registered Address
    Cyber One Unit No. 902 Sector 30A, Plot No. 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703
  • Industry
    Pharma, API Manufacturers
Company report
Solara Active Pharma Sciences Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Solara Active Pharma Sciences Limited report

Financials, compliance, directors, charges, ownership and filings for Solara Active Pharma Sciences Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has one previous CIN (Corporate Identification Number): U24230MH2017PLC291636. The current CIN is L24230MH2017PLC291636, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24230MH2017PLC291636 Current
U24230MH2017PLC291636 Previous

Associated Brands with Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited operates one associated brand: Solara Active Pharma Sciences. These brands represent Solara Active Pharma Sciences Limited's diversified market presence and brand portfolio.

Brand Description Website
Solara Active Pharma Sciences
APIs and intermediates are manufactured for therapeutic categories. solara.co.in

Business Activity of Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited is audited by Delloitte Haskins & Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Delloitte Haskins & Sells LLP (ICAI peer reviewed, certificate valid till 2027-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited is currently managed by 12 directors, with 24 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Poorvank Purohit
Also directs: Solara Active Pharma Sciences Limited
Managing Director 05 Jul 2023 3 Years 0 Months Current
Rajiv Vijay Nabar
Also directs: Solara Active Pharma Sciences Limited, Tac Infosec Limited, Veegen Diet Care Private Limited
Director 14 Nov 2023 2 Years 7 Months Current
Ramakrishnan Rajagopal
Also directs: Solara Active Pharma Sciences Limited, Synthix Global Pharma Solutions Limited, Multivision Business Solutions Private Limited and 1 more
Director 11 Apr 2018 8 Years 2 Months Current
Mohanraj Sanjeevi
Also directs: Solara Active Pharma Sciences Limited
Additional Director 01 Jan 2026 0 Years 6 Months Current
Manish Gupta
Also directs: Solara Active Pharma Sciences Limited, Synthix Global Pharma Solutions Limited, Jagson Pal Pharmaceuticals Limited. and 1 more
Director 22 Jul 2024 1 Years 11 Months Current
Rajendra Kumar Srivastava
Also directs: Solara Active Pharma Sciences Limited, Latticed Advisors Llp, Happiest Minds Technologies Limited and 1 more
Director 14 Nov 2023 2 Years 7 Months Current
Showing 6 of 12 current directors. View all directors

Financials of Solara Active Pharma Sciences Limited FY 2026 filings available

Solara Active Pharma Sciences Limited reported revenue of ₹1,368.98 Cr (up 6.64% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹1,368.98 Cr ▲ 6.64%
Profit · FY 2026
-₹7.41 Cr ▼ 1472.22%
EBITDA · FY 2026
₹192.91 Cr ▼ 10.11%
Revenue₹ Cr · Consolidated01,0002,000FY 2020: ₹1,322 Cr1,322FY 2020FY 2021: ₹1,617 Cr · +22.3% YoY1,617+22.3%FY 2021FY 2022: ₹1,268 Cr · -21.6% YoY1,268-21.6%FY 2022FY 2023: ₹1,444 Cr · +13.8% YoY1,444+13.8%FY 2023FY 2024: ₹1,289 Cr · -10.7% YoY1,289-10.7%FY 2024FY 2025: ₹1,284 Cr · -0.4% YoY1,284-0.4%FY 2025FY 2026: ₹1,369 Cr · +6.6% YoY1,369+6.6%FY 2026
Net Profit₹ Cr · Consolidated-600-400-2000200400FY 2020: ₹115 Cr115FY 2020FY 2021: ₹221 Cr · +93.3% YoY221+93.3%FY 2021FY 2022: ₹58 Cr (loss) · -126.3% YoY-58.3FY 2022FY 2023: ₹22 Cr (loss) · +61.8% YoY-22.2FY 2023FY 2024: ₹567 Cr (loss) · -2449.3% YoY-567FY 2024FY 2025: ₹1 Cr · +100.1% YoY0.5+100.1%FY 2025FY 2026: ₹7 Cr (loss) · -1472.2% YoY-7.4FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0200400Q1'25: ₹363 Cr · +3.2% YoY363+3.2%Q1'25Q2'25: ₹347 Cr · -18.4% YoY347-18.4%Q2'25Q3'25: ₹300 Cr · +20.7% YoY300+20.7%Q3'25Q4'25: ₹273 Cr · -8.8% YoY273-8.8%Q4'25Q1'26: ₹319 Cr · -12.2% YoY319-12.2%Q1'26Q2'26: ₹314 Cr · -9.6% YoY314-9.6%Q2'26Q3'26: ₹349 Cr · +16.2% YoY349+16.2%Q3'26Q4'26: ₹387 Cr · +41.9% YoY387+41.9%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹1,368.98 Cr ₹1,283.76 Cr ₹1,288.92 Cr ₹1,443.81 Cr ₹1,268.34 Cr ₹1,616.88 Cr ₹1,321.75 Cr
Other Income ₹6.16 Cr ₹8.32 Cr ₹5.37 Cr ₹22.55 Cr ₹20.02 Cr ₹28.77 Cr ₹27.52 Cr
Total Income ₹1,375.14 Cr ₹1,292.08 Cr ₹1,294.29 Cr ₹1,466.36 Cr ₹1,288.36 Cr ₹1,645.65 Cr ₹1,349.27 Cr
Cost of Materials Consumed ₹672.77 Cr ₹581.66 Cr ₹760.65 Cr ₹773.89 Cr ₹858.86 Cr ₹683.77 Cr ₹602.15 Cr
Purchases of Stock-in-Trade ₹3.49 Cr ₹5.75 Cr ₹5.1 Cr ₹7.88 Cr ₹53.78 Cr ₹42.8 Cr ₹29.67 Cr
Changes in Inventories ₹8.25 Cr ₹39 Cr ₹39.27 Cr ₹7.05 Cr -₹258.75 Cr -₹2.15 Cr -₹32.95 Cr
Employee Benefit Expense ₹219.2 Cr ₹211.69 Cr ₹243.92 Cr ₹228.63 Cr ₹236.34 Cr ₹229.37 Cr ₹204.13 Cr
Finance Costs ₹94.75 Cr ₹114.81 Cr ₹105.11 Cr ₹90.06 Cr ₹75.28 Cr ₹84.48 Cr ₹77.89 Cr
Depreciation & Amortisation ₹99.68 Cr ₹99.25 Cr ₹103.33 Cr ₹111.19 Cr ₹112.32 Cr ₹108.66 Cr ₹94.16 Cr
Other Expenses ₹278.52 Cr ₹239.38 Cr ₹335.16 Cr ₹292.47 Cr ₹298.14 Cr ₹277.22 Cr ₹259.31 Cr
Total Expenses ₹1,376.66 Cr ₹1,291.54 Cr ₹1,592.54 Cr ₹1,511.17 Cr ₹1,375.97 Cr ₹1,424.15 Cr ₹1,234.36 Cr
Profit Before Exceptional Items & Tax -₹1.52 Cr ₹54 Lakh -₹298.25 Cr -₹44.81 Cr -₹87.61 Cr ₹221.5 Cr ₹114.91 Cr
Exceptional Items -₹5.89 Cr ₹0 -₹190.17 Cr ₹0 -₹3.49 Cr ₹0 ₹0
Profit Before Tax -₹7.41 Cr ₹54 Lakh -₹488.42 Cr -₹44.81 Cr -₹91.1 Cr ₹221.5 Cr ₹114.91 Cr
Total Tax Expense ₹0 ₹0 ₹78.54 Cr -₹22.57 Cr -₹32.81 Cr ₹15 Lakh ₹39 Lakh
Net Profit -₹7.41 Cr ₹54 Lakh -₹566.96 Cr -₹22.24 Cr -₹58.29 Cr ₹221.35 Cr ₹114.52 Cr
  attributable to Owners -₹7.41 Cr ₹54 Lakh -₹567.39 Cr -₹22.17 Cr -₹58.15 Cr ₹221.4 Cr ₹110.9 Cr
  attributable to NCI ₹0 -₹10,000 ₹43 Lakh -₹7 Lakh -₹14 Lakh -₹5 Lakh -₹9 Lakh
Other Comprehensive Income ₹2.85 Cr ₹98 Lakh ₹49 Lakh -₹2.06 Cr ₹1.89 Cr -₹2.4 Cr -₹3.71 Cr
Total Comprehensive Income -₹4.56 Cr ₹1.52 Cr -₹566.47 Cr -₹24.3 Cr -₹56.4 Cr ₹218.95 Cr ₹110.81 Cr
EBITDA (computed) ₹192.91 Cr ₹214.6 Cr -₹89.81 Cr ₹156.44 Cr ₹99.99 Cr ₹414.64 Cr ₹286.96 Cr
Basic EPS ₹-1.68 ₹0.14 ₹-157.62 ₹-6.16 ₹-16.18 ₹69.00 ₹44.29
Diluted EPS ₹-1.68 ₹0.14 ₹-157.62 ₹-6.16 ₹-16.18 ₹64.52 ₹42.82
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹2,332.59 Cr ₹2,231.84 Cr ₹2,350.96 Cr ₹2,899.06 Cr
Non-current Assets ₹1,474.49 Cr ₹1,503.11 Cr ₹1,550.21 Cr ₹1,711.74 Cr
Current Assets ₹858.1 Cr ₹728.73 Cr ₹788.07 Cr ₹1,187.32 Cr
Property, Plant & Equipment ₹793.18 Cr ₹738.68 Cr ₹857.85 Cr ₹920.58 Cr
Inventories ₹317.87 Cr ₹317.9 Cr ₹359.7 Cr ₹558.09 Cr
Trade Receivables ₹438.72 Cr ₹326.57 Cr ₹348.52 Cr ₹536.99 Cr
Cash & Equivalents ₹4.48 Cr ₹3.95 Cr ₹8.44 Cr ₹8.73 Cr
Equity (Net Worth) ₹1,255.55 Cr ₹1,096.91 Cr ₹936.58 Cr ₹1,502.46 Cr
Equity Share Capital ₹44.51 Cr ₹40.25 Cr ₹36 Cr ₹36 Cr
Borrowings (Non-current) ₹110.45 Cr ₹113.86 Cr ₹105.83 Cr ₹235.1 Cr
Borrowings (Current) ₹554.09 Cr ₹662.2 Cr ₹894.06 Cr ₹766.05 Cr
Total Debt (computed) ₹664.54 Cr ₹776.06 Cr ₹999.89 Cr ₹1,001.15 Cr
Current Liabilities ₹893.91 Cr ₹944.11 Cr ₹1,242.79 Cr ₹1,100.9 Cr
Total Liabilities ₹1,077.04 Cr ₹1,134.93 Cr ₹1,414.38 Cr ₹1,396.6 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹152.91 Cr ₹212.82 Cr ₹108.87 Cr ₹156.25 Cr -₹242.09 Cr
Investing Cash Flow -₹98.83 Cr -₹36.83 Cr -₹3.51 Cr -₹81.14 Cr -₹242.82 Cr
Financing Cash Flow -₹53.55 Cr -₹180.48 Cr -₹105.65 Cr -₹112.76 Cr ₹333.6 Cr
Capital Expenditure ₹52.82 Cr ₹39.94 Cr ₹41.06 Cr ₹111.31 Cr ₹208.59 Cr
Free Cash Flow (computed) ₹100.09 Cr ₹172.88 Cr ₹67.81 Cr ₹44.94 Cr -₹450.68 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹10.78 Cr
Net Change in Cash ₹53 Lakh -₹4.49 Cr -₹29 Lakh -₹37.65 Cr -₹151.31 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹387.29 Cr ₹349 Cr ₹313.54 Cr ₹319.15 Cr ₹273.01 Cr ₹300.31 Cr ₹346.95 Cr ₹363.49 Cr ₹299.43 Cr ₹248.73 Cr ₹425.24 Cr ₹352.31 Cr
Other Income ₹4.69 Cr ₹0 ₹49 Lakh ₹98 Lakh ₹5.95 Cr ₹1.49 Cr ₹32 Lakh ₹56 Lakh ₹1.7 Cr ₹45 Lakh ₹1.18 Cr ₹2.04 Cr
Total Income ₹391.98 Cr ₹349 Cr ₹314.03 Cr ₹320.13 Cr ₹278.96 Cr ₹301.8 Cr ₹347.27 Cr ₹364.05 Cr ₹301.13 Cr ₹249.18 Cr ₹426.42 Cr ₹354.35 Cr
Cost of Materials Consumed ₹182.23 Cr ₹175.71 Cr ₹149.69 Cr ₹165.14 Cr ₹143.67 Cr ₹143.96 Cr ₹156.93 Cr ₹137.1 Cr ₹158.38 Cr ₹157.76 Cr ₹241.83 Cr ₹202.68 Cr
Purchases of Stock-in-Trade ₹77 Lakh ₹2.72 Cr ₹0 ₹0 ₹5.05 Cr ₹0 ₹70 Lakh ₹0 ₹15 Lakh ₹25 Lakh ₹3.12 Cr ₹1.58 Cr
Changes in Inventories ₹14.44 Cr ₹8.17 Cr ₹4.31 Cr -₹18.67 Cr -₹30.63 Cr -₹9.1 Cr ₹14.26 Cr ₹64.47 Cr ₹1.45 Cr ₹57.51 Cr -₹7.42 Cr -₹12.27 Cr
Employee Benefit Expense ₹55.47 Cr ₹55.23 Cr ₹54.86 Cr ₹53.64 Cr ₹52.29 Cr ₹51.67 Cr ₹52.71 Cr ₹55.02 Cr ₹56.01 Cr ₹62.64 Cr ₹64.12 Cr ₹61.15 Cr
Finance Costs ₹27.57 Cr ₹22.45 Cr ₹20.83 Cr ₹23.9 Cr ₹29.12 Cr ₹26.54 Cr ₹28.28 Cr ₹30.87 Cr ₹30.69 Cr ₹25.37 Cr ₹24.44 Cr ₹24.61 Cr
Depreciation & Amortisation ₹26.04 Cr ₹25.57 Cr ₹24.49 Cr ₹23.58 Cr ₹24.3 Cr ₹24.54 Cr ₹25.34 Cr ₹25.07 Cr ₹25.25 Cr ₹25.96 Cr ₹26.21 Cr ₹25.91 Cr
Other Expenses ₹76.72 Cr ₹69.83 Cr ₹69.95 Cr ₹62.02 Cr ₹57.26 Cr ₹56.1 Cr ₹61.04 Cr ₹64.98 Cr ₹73.68 Cr ₹132.26 Cr ₹85.96 Cr ₹80.05 Cr
Total Expenses ₹383.24 Cr ₹359.68 Cr ₹324.13 Cr ₹309.61 Cr ₹281.06 Cr ₹293.71 Cr ₹339.26 Cr ₹377.51 Cr ₹345.61 Cr ₹461.75 Cr ₹438.26 Cr ₹383.71 Cr
Profit Before Exceptional Items & Tax ₹8.74 Cr -₹10.68 Cr -₹10.1 Cr ₹10.52 Cr -₹2.1 Cr ₹8.09 Cr ₹8.01 Cr -₹13.46 Cr -₹44.48 Cr -₹212.57 Cr -₹11.84 Cr -₹29.36 Cr
Exceptional Items ₹86 Lakh -₹6.75 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -₹122.18 Cr -₹62.77 Cr -₹5.22 Cr ₹0
Profit Before Tax ₹9.6 Cr -₹17.43 Cr -₹10.1 Cr ₹10.52 Cr -₹2.1 Cr ₹8.09 Cr ₹8.01 Cr -₹13.46 Cr -₹166.66 Cr -₹275.34 Cr -₹17.06 Cr -₹29.36 Cr
Total Tax Expense ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹88.79 Cr ₹0 ₹0 -₹10.25 Cr
Net Profit ₹9.6 Cr -₹17.43 Cr -₹10.1 Cr ₹10.52 Cr -₹2.1 Cr ₹8.09 Cr ₹8.01 Cr -₹13.46 Cr -₹255.45 Cr -₹275.34 Cr -₹17.06 Cr -₹19.11 Cr
  attributable to Owners ₹9.6 Cr -₹17.43 Cr -₹10.1 Cr ₹10.52 Cr -₹2.1 Cr ₹8.09 Cr - -₹13.47 Cr -₹255.34 Cr -₹275.34 Cr -₹17.16 Cr -₹19.55 Cr
  attributable to NCI ₹0 ₹0 ₹0 ₹0 -₹10,000 ₹0 - ₹0 -₹11 Lakh ₹0 ₹10 Lakh ₹44 Lakh
Other Comprehensive Income ₹50 Lakh ₹1.55 Cr ₹81 Lakh -₹1 Lakh -₹62 Lakh -₹7 Lakh ₹1.68 Cr -₹1 Lakh ₹30 Lakh -₹4 Lakh ₹23 Lakh ₹0
Total Comprehensive Income ₹10.1 Cr -₹15.88 Cr -₹9.29 Cr ₹10.51 Cr -₹2.72 Cr ₹8.02 Cr ₹9.69 Cr -₹13.47 Cr -₹255.15 Cr -₹275.38 Cr -₹16.83 Cr -₹19.11 Cr
EBITDA (computed) ₹62.35 Cr ₹37.34 Cr ₹35.22 Cr ₹58 Cr ₹51.32 Cr ₹59.17 Cr ₹61.63 Cr ₹42.48 Cr ₹11.46 Cr -₹161.24 Cr ₹38.81 Cr ₹21.16 Cr
Basic EPS ₹2.20 ₹-3.98 ₹-2.36 ₹2.46 ₹-0.93 ₹2.03 ₹2.54 ₹-3.50 ₹-70.93 ₹-76.49 ₹-4.77 ₹-5.43
Diluted EPS ₹2.20 ₹-3.98 ₹-2.36 ₹2.46 ₹-0.93 ₹2.03 ₹2.54 ₹-3.50 ₹-70.93 ₹-76.49 ₹-4.77 ₹-5.43
Latest 12 quarters shown of 25 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹1,368.98 Cr ₹1,283.76 Cr ₹1,288.92 Cr ₹1,443.81 Cr ₹1,268.34 Cr ₹1,616.88 Cr ₹1,321.75 Cr
Other Income ₹5.89 Cr ₹9.14 Cr ₹5.37 Cr ₹22.14 Cr ₹18.76 Cr ₹28.41 Cr ₹27.51 Cr
Total Income ₹1,374.87 Cr ₹1,292.9 Cr ₹1,294.29 Cr ₹1,465.95 Cr ₹1,287.1 Cr ₹1,645.29 Cr ₹1,349.26 Cr
Cost of Materials Consumed ₹672.77 Cr ₹581.66 Cr ₹760.66 Cr ₹773.9 Cr ₹858.86 Cr ₹683.76 Cr ₹602.15 Cr
Purchases of Stock-in-Trade ₹3.49 Cr ₹5.75 Cr ₹5.1 Cr ₹7.88 Cr ₹53.78 Cr ₹42.8 Cr ₹29.67 Cr
Changes in Inventories ₹8.25 Cr ₹39 Cr ₹39.27 Cr ₹7.05 Cr -₹258.75 Cr -₹2.15 Cr -₹32.95 Cr
Employee Benefit Expense ₹219.2 Cr ₹211.68 Cr ₹243.92 Cr ₹228.05 Cr ₹234.2 Cr ₹227.63 Cr ₹202.24 Cr
Finance Costs ₹94.24 Cr ₹114.81 Cr ₹105.97 Cr ₹90.06 Cr ₹75.27 Cr ₹84.47 Cr ₹77.88 Cr
Depreciation & Amortisation ₹99.68 Cr ₹99.25 Cr ₹103.03 Cr ₹110.9 Cr ₹112.01 Cr ₹108.31 Cr ₹93.67 Cr
Other Expenses ₹278.59 Cr ₹241.83 Cr ₹335.04 Cr ₹292.89 Cr ₹299.9 Cr ₹279.51 Cr ₹264.11 Cr
Total Expenses ₹1,376.22 Cr ₹1,293.98 Cr ₹1,592.99 Cr ₹1,510.73 Cr ₹1,375.27 Cr ₹1,424.33 Cr ₹1,236.77 Cr
Profit Before Exceptional Items & Tax -₹1.35 Cr -₹1.08 Cr -₹298.7 Cr -₹44.78 Cr -₹88.17 Cr ₹220.96 Cr ₹112.49 Cr
Exceptional Items -₹5.89 Cr ₹0 -₹189.64 Cr ₹0 -₹3.49 Cr ₹0 ₹0
Profit Before Tax -₹7.24 Cr -₹1.08 Cr -₹488.34 Cr -₹44.78 Cr -₹91.66 Cr ₹220.96 Cr ₹112.49 Cr
Total Tax Expense ₹0 ₹0 ₹78.54 Cr -₹22.57 Cr -₹33.1 Cr ₹0 ₹0
Net Profit -₹7.24 Cr -₹1.08 Cr -₹566.88 Cr -₹22.21 Cr -₹58.56 Cr ₹220.96 Cr ₹112.49 Cr
Other Comprehensive Income ₹3.27 Cr ₹1.06 Cr ₹56 Lakh -₹1.76 Cr ₹2.01 Cr -₹2.53 Cr -₹3.29 Cr
Total Comprehensive Income -₹3.97 Cr -₹2 Lakh -₹566.32 Cr -₹23.97 Cr -₹56.55 Cr ₹218.43 Cr ₹109.2 Cr
EBITDA (computed) ₹192.57 Cr ₹212.98 Cr -₹89.7 Cr ₹156.18 Cr ₹99.11 Cr ₹413.74 Cr ₹284.04 Cr
Basic EPS ₹-1.64 ₹-0.27 ₹-157.48 ₹-6.17 ₹-16.29 ₹68.86 ₹43.47
Diluted EPS ₹-1.64 ₹-0.27 ₹-157.48 ₹-6.17 ₹-16.29 ₹64.40 ₹42.03
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹2,276.59 Cr ₹2,225.1 Cr ₹2,346.6 Cr ₹2,894.95 Cr
Non-current Assets ₹1,467.9 Cr ₹1,496.5 Cr ₹1,555.95 Cr ₹1,704.08 Cr
Current Assets ₹808.69 Cr ₹728.6 Cr ₹790.65 Cr ₹1,190.87 Cr
Property, Plant & Equipment ₹786.58 Cr ₹732.08 Cr ₹851.24 Cr ₹913.97 Cr
Inventories ₹317.87 Cr ₹317.9 Cr ₹359.7 Cr ₹558.09 Cr
Trade Receivables ₹438.87 Cr ₹326.57 Cr ₹351.22 Cr ₹539.65 Cr
Cash & Equivalents ₹4 Cr ₹3.81 Cr ₹8.32 Cr ₹8.55 Cr
Equity (Net Worth) ₹1,255.44 Cr ₹1,096.21 Cr ₹937.42 Cr ₹1,503.13 Cr
Equity Share Capital ₹44.51 Cr ₹40.25 Cr ₹36 Cr ₹36 Cr
Borrowings (Non-current) ₹60.94 Cr ₹113.86 Cr ₹105.83 Cr ₹235.1 Cr
Borrowings (Current) ₹554.09 Cr ₹662.2 Cr ₹893.55 Cr ₹766.05 Cr
Total Debt (computed) ₹615.03 Cr ₹776.06 Cr ₹999.38 Cr ₹1,001.15 Cr
Current Liabilities ₹887.53 Cr ₹938.07 Cr ₹1,237.65 Cr ₹1,096.12 Cr
Total Liabilities ₹1,021.15 Cr ₹1,128.89 Cr ₹1,409.18 Cr ₹1,391.82 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹152.89 Cr ₹212.8 Cr ₹110.95 Cr ₹156.17 Cr -₹241.79 Cr
Investing Cash Flow -₹50.14 Cr -₹36.83 Cr -₹4.66 Cr -₹81.13 Cr -₹243.07 Cr
Financing Cash Flow -₹102.56 Cr -₹180.48 Cr -₹106.52 Cr -₹112.76 Cr ₹333.6 Cr
Capital Expenditure ₹52.82 Cr ₹39.94 Cr ₹43.07 Cr ₹111.31 Cr ₹208.86 Cr
Free Cash Flow (computed) ₹100.07 Cr ₹172.86 Cr ₹67.88 Cr ₹44.86 Cr -₹450.65 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹10.78 Cr
Net Change in Cash ₹19 Lakh -₹4.51 Cr -₹23 Lakh -₹37.72 Cr -₹151.26 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹387.29 Cr ₹349 Cr ₹313.54 Cr ₹319.15 Cr ₹273.01 Cr ₹300.31 Cr ₹346.95 Cr ₹363.49 Cr ₹299.43 Cr ₹248.73 Cr ₹425.24 Cr ₹352.31 Cr
Other Income ₹4.42 Cr ₹0 ₹49 Lakh ₹98 Lakh ₹5.95 Cr ₹1.49 Cr ₹32 Lakh ₹1.38 Cr ₹1.63 Cr ₹44 Lakh ₹1.23 Cr ₹2.07 Cr
Total Income ₹391.71 Cr ₹349 Cr ₹314.03 Cr ₹320.13 Cr ₹278.96 Cr ₹301.8 Cr ₹347.27 Cr ₹364.87 Cr ₹301.06 Cr ₹249.17 Cr ₹426.47 Cr ₹354.38 Cr
Cost of Materials Consumed ₹182.23 Cr ₹175.71 Cr ₹149.69 Cr ₹165.14 Cr ₹143.67 Cr ₹143.96 Cr ₹156.93 Cr ₹137.1 Cr ₹158.39 Cr ₹157.76 Cr ₹241.83 Cr ₹202.68 Cr
Purchases of Stock-in-Trade ₹77 Lakh ₹2.72 Cr ₹0 ₹0 ₹5.05 Cr ₹0 ₹70 Lakh ₹0 ₹15 Lakh ₹25 Lakh ₹3.12 Cr ₹1.58 Cr
Changes in Inventories ₹14.44 Cr ₹8.17 Cr ₹4.31 Cr -₹18.67 Cr -₹30.63 Cr -₹9.1 Cr ₹14.26 Cr ₹64.47 Cr ₹1.45 Cr ₹57.51 Cr -₹7.42 Cr -₹12.27 Cr
Employee Benefit Expense ₹55.47 Cr ₹55.23 Cr ₹54.86 Cr ₹53.64 Cr ₹52.28 Cr ₹51.67 Cr ₹52.71 Cr ₹55.02 Cr ₹56.01 Cr ₹62.64 Cr ₹64.12 Cr ₹61.15 Cr
Finance Costs ₹27.06 Cr ₹22.45 Cr ₹20.83 Cr ₹23.9 Cr ₹29.12 Cr ₹26.54 Cr ₹28.28 Cr ₹30.87 Cr ₹30.62 Cr ₹25.37 Cr ₹24.47 Cr ₹25.51 Cr
Depreciation & Amortisation ₹26.04 Cr ₹25.57 Cr ₹24.49 Cr ₹23.58 Cr ₹24.3 Cr ₹24.54 Cr ₹25.34 Cr ₹25.07 Cr ₹25.1 Cr ₹25.96 Cr ₹26.14 Cr ₹25.83 Cr
Other Expenses ₹76.83 Cr ₹69.82 Cr ₹69.93 Cr ₹62.01 Cr ₹60.05 Cr ₹56.09 Cr ₹61.03 Cr ₹64.66 Cr ₹73.64 Cr ₹132.24 Cr ₹85.92 Cr ₹80.03 Cr
Total Expenses ₹382.84 Cr ₹359.67 Cr ₹324.11 Cr ₹309.6 Cr ₹283.84 Cr ₹293.7 Cr ₹339.25 Cr ₹377.19 Cr ₹345.36 Cr ₹461.73 Cr ₹438.18 Cr ₹384.51 Cr
Profit Before Exceptional Items & Tax ₹8.87 Cr -₹10.67 Cr -₹10.08 Cr ₹10.53 Cr -₹4.88 Cr ₹8.1 Cr ₹8.02 Cr -₹12.32 Cr -₹44.3 Cr -₹212.56 Cr -₹11.71 Cr -₹30.13 Cr
Exceptional Items ₹86 Lakh -₹6.75 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -₹123.32 Cr -₹62.77 Cr -₹3.55 Cr ₹0
Profit Before Tax ₹9.73 Cr -₹17.42 Cr -₹10.08 Cr ₹10.53 Cr -₹4.88 Cr ₹8.1 Cr ₹8.02 Cr -₹12.32 Cr -₹167.62 Cr -₹275.33 Cr -₹15.26 Cr -₹30.13 Cr
Total Tax Expense ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹88.79 Cr ₹0 ₹0 -₹10.25 Cr
Net Profit ₹9.73 Cr -₹17.42 Cr -₹10.08 Cr ₹10.53 Cr -₹4.88 Cr ₹8.1 Cr ₹8.02 Cr -₹12.32 Cr -₹256.41 Cr -₹275.33 Cr -₹15.26 Cr -₹19.88 Cr
Other Comprehensive Income ₹71 Lakh ₹1.6 Cr ₹96 Lakh ₹0 -₹64 Lakh ₹0 ₹1.7 Cr ₹0 ₹32 Lakh ₹0 ₹24 Lakh ₹0
Total Comprehensive Income ₹10.44 Cr -₹15.82 Cr -₹9.12 Cr ₹10.53 Cr -₹5.52 Cr ₹8.1 Cr ₹9.72 Cr -₹12.32 Cr -₹256.09 Cr -₹275.33 Cr -₹15.02 Cr -₹19.88 Cr
EBITDA (computed) ₹61.97 Cr ₹37.35 Cr ₹35.24 Cr ₹58.01 Cr ₹48.54 Cr ₹59.18 Cr ₹61.64 Cr ₹43.62 Cr ₹11.42 Cr -₹161.23 Cr ₹38.9 Cr ₹21.21 Cr
Basic EPS ₹2.23 ₹-3.97 ₹-2.36 ₹2.46 ₹-1.65 ₹2.47 ₹2.11 ₹-3.20 ₹-71.23 ₹-76.49 ₹-4.24 ₹-5.52
Diluted EPS ₹2.23 ₹-3.97 ₹-2.36 ₹2.46 ₹-1.65 ₹2.47 ₹2.11 ₹-3.20 ₹-71.23 ₹-76.49 ₹-4.24 ₹-5.52
Latest 12 quarters shown of 24 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Solara Active Pharma Sciences Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Solara Active Pharma Sciences Limited

As per the shareholding pattern filed with NSE for the quarter ended May 2026, promoters hold 42.00%, foreign institutional investors hold 11.33%, domestic institutional investors hold 3.78%, retail and other public shareholders hold 42.89% of Solara Active Pharma Sciences Limited. The company had 70,037 shareholders on record.

Promoters: 42.00%DII (Domestic Institutional): 3.78%FII (Foreign Institutional): 11.33%Retail & Others: 42.89%
May 2026
QUARTER
42.00% Promoters
3.78% DII (Domestic Institutional)
11.33% FII (Foreign Institutional)
42.89% Retail & Others
Promoter holding - history
Now 42.00% · May 2026High 44.69% · Sep 2020Low 30.49% · Dec 2023
29%33.3%37.5%41.8%46%Jun 2018Jun 2020Jun 2022Jun 2024May 2026Jun 2018: 35.81%Sep 2018: 37.90%Dec 2018: 37.90%Mar 2019: 40.55%Jun 2019: 40.55%Sep 2019: 40.55%Dec 2019: 40.14%Mar 2020: 41.88%Jun 2020: 41.88%Sep 2020: 44.69%Dec 2020: 44.13%Mar 2021: 44.11%Jun 2021: 41.07%Sep 2021: 41.07%Dec 2021: 39.51%Mar 2022: 39.71%Jun 2022: 40.40%Sep 2022: 40.40%Dec 2022: 40.40%Mar 2023: 40.97%Jun 2023: 39.31%Sep 2023: 37.19%Dec 2023: 30.49%Mar 2024: 30.49%Jun 2024: 37.27%Sep 2024: 37.27%Dec 2024: 37.23%Mar 2025: 37.94%Jun 2025: 42.01%Sep 2025: 42.01%Dec 2025: 42.00%Mar 2026: 42.00%May 2026: 42.00%44.69%30.49%42.00%
Shareholding trend - last 6 quarters
May 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025
Promoters42.00%42.00%42.00%42.01%42.01%37.94%
Public58.00%58.00%58.00%57.99%57.99%62.06%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
Promoters42.00%37.94%30.49%40.97%39.71%44.11%41.88%40.55%
Public58.00%62.06%69.51%59.03%60.29%55.89%58.12%59.45%
Promoter change (YoY, %pts)+4.06+7.45-10.48+1.26-4.40+2.23+1.33-

Board & Governance of Solara Active Pharma Sciences Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Solara Active Pharma Sciences Limited has 8 directors - 4 independent and 2 executive. The board is chaired by Ramakrishnan Rajagopal.

DirectorPositionOn board sinceListed boards
Ramakrishnan Rajagopal Non-Executive - Independent Director · Chairperson 2018-04-11 1
Kausalya Santhanam Non-Executive - Independent Director 2018-04-11 2
Arun Kumar Pillai Non-Executive - Non Independent Director 2021-08-04 3
Sandeep Shashikantha Rao Executive Director · CEO-MD 2025-02-21 1
Manish Gupta Non-Executive - Non Independent Director 2024-07-22 2
Rajendra Kumar Srivastava Non-Executive - Independent Director 2023-11-14 2
Rajiv Vijay Nabar Non-Executive - Independent Director 2023-11-14 2
Mohanraj Sanjeevi Executive Director 2026-01-01 1
Board Committees
CommitteeMembers
Audit Committee Ramakrishnan Rajagopal (Chairperson), Kausalya Santhanam, Rajendra Kumar Srivastava, Rajiv Vijay Nabar
Nomination and remuneration committee Rajendra Kumar Srivastava (Chairperson), Kausalya Santhanam, Rajiv Vijay Nabar, Ramakrishnan Rajagopal
Stakeholders Relationship Committee Kausalya Santhanam (Chairperson), Sandeep Shashikantha Rao, Manish Gupta
Risk Management Committee Rajiv Vijay Nabar (Chairperson), Kausalya Santhanam, Rajendra Kumar Srivastava, Ramakrishnan Rajagopal, Sandeep Shashikantha Rao
Corporate Social Responsibility Committee Kausalya Santhanam (Chairperson), Ramakrishnan Rajagopal, Sandeep Shashikantha Rao

Group Structure of Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has 2 subsidiary companies. This group structure data is as of FY 2023. The corporate group structure reflects Solara Active Pharma Sciences Limited's business expansion strategy and organizational complexity.

2
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Sequent Penems Private Limited U24233KA2010PTC053548 -
Chemsynth Laboratories Private Limited U24297TG2009PTC064991 -

Showing major subsidiaries. Total: 2.

Charges & Borrowings of Solara Active Pharma Sciences Limited

Open charges
₹1,799.4 Cr
Satisfied charges
₹2,310.69 Cr
Breakdown by lending institutions
Others₹1,659.40 Cr
Yes Bank Limited₹140.00 Cr
Latest charge details
DateLenderAmountStatus
30 Jan 2025 Others ₹75 Cr Open
28 Sep 2022 Yes Bank Limited ₹65 Cr Open
28 Sep 2022 Yes Bank Limited ₹75 Cr Open
22 Nov 2021 Others ₹150 Cr Open
21 Jan 2021 Others ₹170 Cr Open

Total charge records: 26 View all charges

Employees and EPFO Compliance at Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has a workforce of 1,656 employees as of Mar 25, 2024.

Employee count
1,656
Active EPFO establishments
7
Employee growth
6.29%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Solara Active Pharma Sciences Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Solara Active Pharma Sciences Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Solara Active Pharma Sciences Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Solara Active Pharma Sciences Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Solara Active Pharma Sciences Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Solara Active Pharma Sciences Limited

MSME Payment Delays by Solara Active Pharma Sciences Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Solara Active Pharma Sciences Limited

Subsidiaries & Group Companies of Solara Active Pharma Sciences Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Solara Active Pharma Sciences Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Solara Active Pharma Sciences Limited

MCA Filings & Documents of Solara Active Pharma Sciences Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Solara Active Pharma Sciences Limited

Directors
01 Jan 2026
Mohanraj Sanjeevi was appointed as a Additional Director on 01 Jan 2026 & has been associated with this company since 6 months 7 days.
Activity
25 Sep 2025
Solara Active Pharma Sciences Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Directors
02 Apr 2025
Sandeep Shashikantha Rao was appointed as a Ceo on 02 Apr 2025 & has been associated with this company since 1 year 3 months.
Directors
02 Apr 2025
Sarat Kumar Asuri was appointed as a Cfo on 02 Apr 2025 & has been associated with this company since 1 year 3 months.
Activity
31 Mar 2025
Solara Active Pharma Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Directors
21 Feb 2025
Sandeep Shashikantha Rao was appointed as a CEO on 21 Feb 2025 & has been associated with this company since 1 year 4 months.

Recent News on Solara Active Pharma Sciences Limited

Stocks that will see action: January 24, 2025
24 Jan 2025 · Thehindubusinessline

Frequently Asked Questions about Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited is an active public limited company in the pharma sector based in Thane, Maharashtra, India. It was incorporated on 23 February 2017 (9+ years old) and is registered under CIN L24230MH2017PLC291636. Listed on BSE: 541540 and NSE: SOLARA. The company has 1,656 employees.

Solara Active Pharma Sciences Limited reported revenue of ₹1,292.08 Cr for FY 2025 (up 0.00% YoY).

The current directors of Solara Active Pharma Sciences Limited are:

The primary industry of Solara Active Pharma Sciences Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Solara Active Pharma Sciences Limited is listed on both BSE (code: 541540) and NSE (symbol: SOLARA).

Solara Active Pharma Sciences Limited can be reached at the registered office: Cyber One Unit No. 902 Sector 30A, Plot No. 4 & 6 Vashi Navi Mumbai, Thane, Maharashtra, India – 400703, or through the website solara.co.in.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available